IBRX
NASDAQ
$7.50
ImmunityBio Inc (IBRX)
ImmunityBio, Inc., an immunotherapy company, develops a memory T-cell cancer vaccine to fight multiple types of tumors without the use of high-dose chemotherapy.
Sector:
Healthcare
Industry:
Biotechnology
Strong Buy
Target: $13 (+73.45%)
Market Cap
$8.10B
Revenue 5Y CAGR
+200.12%
Free Cash Flow Yield
-3.69%
Beta (5Y)
1.56
Price Chart
Valuation
Market Cap$8.10B
P/S57.87
Profitability
Total Revenue (TTM)$141M
Gross Profit (TTM)$140M
EBITDA-$245M
Operating Margin-157.9%
EPS-$0.83
Financial Health
Debt-to-Equity-0.1%
Free Cash Flow Yield-3.69%
Growth & Risk
EPS 5Y CAGR-9.78%
Revenue 5Y CAGR+200.12%
FCF 5Y CAGR+5.55%
Beta (5Y)1.56
Sharpe Ratio1.38